Rarely is there anything divulged during the Q1 cc. We know revs will be between $7-8M since the quarter was practically over when revs are known. We expect revs for Q2 to be about $8.5M where there will be an update here as to the reality since we’ll be through half the quarter. There will be the update on generic oxy that they are waiting to hear back from the FDA after the full filing has been completed. It will primarily be a regurgitation from the YE cc.
What we will see is our first glimpse into the profitability post-Lannett. This was Nasrat’s short-term concern until revenues start picking up. The good thing is we have a cash reserve and the Nasrat credit line we can tap into for liquidity, inventory and distribution needs.
Would love to hear about a new CFO coming on board, but they may be waiting until after the cc.
News 
Market Data 
Discover 
